Renal impairment, C. difficile recurrence, and the differential effect of bezlotoxumab: A post hoc analysis of pooled data from 2 randomized clinical trials

Yoav Golan, Herbert L. DuPont, Fernando Aldomiro, Erin H. Jensen, Mary E. Hanson, Mary Beth Dorr

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background. Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti-toxin B monoclonal antibody, in reducing rCDI in participants with renal impairment. Methods. We pooled data from 2 randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trials conducted in participants receiving bezlotoxumab or placebo infusion during oral antibacterial drug treatment for CDI. We assessed the association between renal impairment and rCDI in placebo-treated participants and evaluated the effect of bezlotoxumab vs placebo in reducing rCDI among participants with renal impairment, defined as an estimated glomerular filtration rate <90 mL/min. Results. The proportion of placebo-treated participants experiencing rCDI within 12 weeks was higher in those with renal impairment (n = 919) vs those without renal impairment (n = 612; 36.6% and 27.7%, respectively; difference, 8.9%; 95% CI, 1.3% to 16.3%). Renal impairment was significantly associated with a higher rate of recurrence in placebo-treated participants lacking commonly recognized risk factors for rCDI (renal impairment as only risk factor, 28.8%; vs normal renal function and no risk factors, 12.5%; difference, 16.3%; 95% CI, 3.4% to 28.8%). Among all participants with renal impairment, the rate of rCDI was 19.5% among bezlotoxumab-treated vs 36.6% among placebo-treated participants (difference, -17.1%; 95% CI, -23.4% to -10.6%). Conclusions. This post hoc analysis adds to the literature suggesting an association of renal impairment as an independent risk factor for rCDI and provides preliminary evidence that patients with renal impairment who suffer with CDI may benefit from adjunctive treatment with bezlotoxumab.

Original languageEnglish
Article numberofaa248
JournalOpen Forum Infectious Diseases
Volume7
Issue number7
DOIs
StatePublished - 1 Jul 2020
Externally publishedYes

Keywords

  • Bezlotoxumab
  • Clostridioides difficile
  • Recurrence
  • Renal dysfunction

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Renal impairment, C. difficile recurrence, and the differential effect of bezlotoxumab: A post hoc analysis of pooled data from 2 randomized clinical trials'. Together they form a unique fingerprint.

Cite this